SELECT * FROM `stock_list` WHERE `symbol` = "RENB" and stock_list.exchange IN (SELECT exchange FROM gurufocu_main.stock_list_exchanges where country='USA' and active=1) limit 0,1
SELECT * FROM `stock_list` where symbol='RENB' AND exchange = 'NAS' limit 0,1
SELECT * FROM `stock_list` WHERE `symbol` = "RENB" and stock_list.exchange IN (SELECT exchange FROM gurufocu_main.stock_list_exchanges where country='USA' and active=1) limit 0,1 RENB (Renovaro) Asset Turnover
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Renovaro Inc (NAS:RENB) » Definitions » Asset Turnover

Renovaro (Renovaro) Asset Turnover : 0.00 (As of Dec. 2023)


View and export this data going back to 2014. Start your Free Trial

What is Renovaro Asset Turnover?

Asset Turnover measures how quickly a company turns over its asset through sales. It is calculated as Revenue divided by Total Assets. Renovaro's Revenue for the three months ended in Dec. 2023 was $0.00 Mil. Renovaro's Total Assets for the quarter that ended in Dec. 2023 was $57.79 Mil. Therefore, Renovaro's Asset Turnover for the quarter that ended in Dec. 2023 was 0.00.

Asset Turnover is linked to ROE % through Du Pont Formula. Renovaro's annualized ROE % for the quarter that ended in Dec. 2023 was -40.11%. It is also linked to ROA % through Du Pont Formula. Renovaro's annualized ROA % for the quarter that ended in Dec. 2023 was -31.35%.


Renovaro Asset Turnover Historical Data

The historical data trend for Renovaro's Asset Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Renovaro Asset Turnover Chart

Renovaro Annual Data
Trend Mar13 Dec14 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Asset Turnover
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Renovaro Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Asset Turnover Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Renovaro's Asset Turnover

For the Biotechnology subindustry, Renovaro's Asset Turnover, along with its competitors' market caps and Asset Turnover data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Renovaro's Asset Turnover Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Renovaro's Asset Turnover distribution charts can be found below:

* The bar in red indicates where Renovaro's Asset Turnover falls into.



Renovaro Asset Turnover Calculation

Asset Turnover measures how quickly a company turns over its asset through sales.

Renovaro's Asset Turnover for the fiscal year that ended in Jun. 2023 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (A: Jun. 2023 )/( (Total Assets (A: Jun. 2022 )+Total Assets (A: Jun. 2023 ))/ count )
=0/( (84.633+58.301)/ 2 )
=0/71.467
=0.00

Renovaro's Asset Turnover for the quarter that ended in Dec. 2023 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (Q: Dec. 2023 )/( (Total Assets (Q: Sep. 2023 )+Total Assets (Q: Dec. 2023 ))/ count )
=0/( (57.563+58.018)/ 2 )
=0/57.7905
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Companies with low profit margins tend to have high Asset Turnover, while those with high profit margins have low Asset Turnover. Companies in the retail industry tend to have a very high turnover ratio.


Renovaro  (NAS:RENB) Asset Turnover Explanation

Asset Turnover is linked to ROE % through Du Pont Formula.

Renovaro's annulized ROE % for the quarter that ended in Dec. 2023 is

ROE %**(Q: Dec. 2023 )
=Net Income/Total Stockholders Equity
=-18.116/45.171
=(Net Income / Revenue)*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-18.116 / 0)*(0 / 57.7905)*(57.7905/ 45.171)
=Net Margin %*Asset Turnover*Equity Multiplier
= %*0*1.2794
=ROA %*Equity Multiplier
=-31.35 %*1.2794
=-40.11 %

Note: The Net Income data used here is four times the quarterly (Dec. 2023) net income data. The Revenue data used here is four times the quarterly (Dec. 2023) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** The ROE % used above is for Du Pont Analysis only. It is different from the defined ROE % page on our website, as here it uses Net Income instead of Net Income attributable to Common Stockholders in the calculation.

It is also linked to ROA % through Du Pont Formula:

Renovaro's annulized ROA % for the quarter that ended in Dec. 2023 is

ROA %(Q: Dec. 2023 )
=Net Income/Total Assets
=-18.116/57.7905
=(Net Income / Revenue)*(Revenue / Total Assets)
=(-18.116 / 0)*(0 / 57.7905)
=Net Margin %*Asset Turnover
= %*0
=-31.35 %

Note: The Net Income data used here is four times the quarterly (Dec. 2023) net income data. The Revenue data used here is four times the quarterly (Dec. 2023) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Therefore, it is a good sign if a company's Asset Turnover is consistent or even increases. If a company's asset grows faster than sales, its Asset Turnover will decline, which can be a warning sign.


Renovaro Asset Turnover Related Terms

Thank you for viewing the detailed overview of Renovaro's Asset Turnover provided by GuruFocus.com. Please click on the following links to see related term pages.


Renovaro (Renovaro) Business Description

Traded in Other Exchanges
Address
2080 Century Park East, Suite 906, Los Angeles, CA, USA, 90067
Renovaro Biosciences Inc Formerly Enochian BioSciences Inc is a biopharmaceutical company. It is engaged in the research and development of pharmaceutical and biological products for the treatment of HIV, HBV, and cancer with the intent to manufacture said products.
Executives
Leni Boeren director 2080 CENTURY PARK EAST, #906, LOS ANGELES CA 90067
Ruud Hendriks director CHATEAU D'AZUR, BLVD D'LTALIE 44, MONACO O9 C11298000
Ole Abildgaard 10 percent owner VEDBAEK STRANDVEJ 506, VEDBAEK G7 2950
Francois Binette officer: Executive Vice President 2022 N. ALVARADO STREET, LOS ANGELES CA 90039
Serhat Gumrukcu 10 percent owner 2080 CENTURY CITY EAST, SUITE 906, LOS ANGELES CA 90067
Rene Sindlev director, 10 percent owner FRUEBJERGVEJ 3 BOX 62, COPENHAGEN G7 2100
Carl Forest Sandler other: Former director see note below 330 EAST 33RD STREET, APARTMENT 3A, NEW YORK FL 10016
Jayne Mcnicol director 606 NORTHERN AVENUE, MILL VALLEY CA 94941
Gregg H Alton director 333 LAKESIDE DRIVE, FOSTER CITY CA 94404
Carol L Brosgart director C/O TOBIRA THERAPEUTICS, INC., 701 GATEWAY BOULEVARD, SOUTH SAN FRANCISCO CA 94080
Henrik Gronfeldt-sorensen director STUMPEDYSSEVEJ 17, HORSHOLM G7 2970
Luisa Puche officer: Chief Financial Officer 318 NE 104TH STREET, MIAMI FL 33138
Luc Debruyne director NOORDENWINDHELLING 2 02/05, OOSTDUINKERKE C9 8670
Anderson Wittekind William 10 percent owner 8581 SANTA MONICA BLVD, LOS ANGELES CA 90069
Leire, Eric Jean Marie director, officer: CEO; President C/O DANDRIT BIOTECH USA, INC., P.O. BOX 189, RANDOLPH VT 05060